TRILLIO a porTable pRescription assistant Improving heaLth of Europeans citizen...
TRILLIO a porTable pRescription assistant Improving heaLth of Europeans citizens by increasing therapeutic adherence in eLderly people and in patIents affected by chrOnic diseases
"Therapeutic adherence is defined as the extent to which a person’s behaviour – taking medication, following a diet, and/or executing lifestyle changes, corresponds with agreed recommendations from a health care provider. It is e...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Información proyecto TRILLIO
Duración del proyecto: 5 meses
Fecha Inicio: 2018-05-09
Fecha Fin: 2018-10-31
Líder del proyecto
LA COMANDA SRL
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
71K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
"Therapeutic adherence is defined as the extent to which a person’s behaviour – taking medication, following a diet, and/or executing lifestyle changes, corresponds with agreed recommendations from a health care provider. It is estimated that each year the poor adherence to medical treatments in Europe causes about 200,000 deaths and burdens on health expenditure up to 80 billion euro a year (AIFA source).
TRILLIO is a therapeutic adherence device really similar to an alarm clock, thus really familiar for elderly. The TRILLIO device is provided with an app that optimizes the connections among various players and organizations who share a common goal: make sure a patient follows his or her pharmaceutical treatment plan. When it's time to take a drug, TRILLIO alerts the user with a sound and a visual alarm, while showing all the relevant information on its 2.7"" e-paper display. If the user doesn't press the button on the device to turn off the alarm within ten minutes, TRILLIO automatically sends a notification to any family member connected to the system. TRILLIO has been already tested in Italy and received serval endorsement by organisations in Italy and abroad.
We are a targeting and overall population composed by 150.000.000 European that are suffering from Chronic diseases, 50% of them have difficulties in following a therapy: we are addressing 0,2% of this market and we are aiming at selling 112.000 devices by 2023, that will generate 17M€ turnover. The Feasibility study will have the purpose to support us in completing the market analysis, in launching a small pilot (i.e. 500/1.000 users), in identifying suitable partners in Europe for wide demo site (i.e. hospitals) and in identifying the right partners for distributing TRILLIO in Europe. TRILLIO is brought on the market by LA COMANDA, an Italian startup established under the Italian act for innovative startup, whose founders are Carlo Brianza and Andrea Gaggi, former executives of Nokia mobile team.
"